 Gain Therapeutics Inc NASDAQ: GANX has presented new preclinical data from its Parkinsons Disease PD program at the 2022 Synuclein Meeting. The data show that the lead compound GT-02287 increases the levels and activity of the beta-glucocerebrosidase GCase protein,. 